Literature DB >> 25778331

Association between estrogen receptor 1 (ESR1) genetic variations and cancer risk: a meta-analysis.

Huiling Sun1, Qiwen Deng, Yuqin Pan, Bangshun He, Houqun Ying, Jie Chen, Xian Liu, Shukui Wang.   

Abstract

PURPOSE: Emerging published reports on the association between estrogen receptor 1 (ESR1) genetic variation and cancer susceptibility are inconsistent. This review and meta- analysis was performed to achieve a more precise evaluation of this relationship.
METHODS: A literature search of PubMed database was conducted from the inception of this study through April 1st 2014. Crude odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated to assess the association.
RESULTS: 87 studies were enrolled in this meta-analysis. The results indicated that PvuII (T>C) polymorphism was associated with an increased risk of hepatocellular carcinoma (HCC) and prostate cancer, in contrast with the decreased risk of gallbladder cancer. No significant association was found in Asian and Caucasian populations. Furthermore, XbaI (A>G) genetic variation was only associated with an increased risk of prostate cancer, but was not related with race. In addition, T594T (G>A) polymorphisms were significantly associated with an increased risk of cancer, especially in Asian populations.
CONCLUSIONS: This meta-analysis indicated that PvuII (T>C) genetic variation may be risk factor for HCC, prostate cancer and gallbladder cancer. Meanwhile, XbaI (A>G) polymorphism may be potential prognostic factor for prostate cancer. Furthermore, T594T (G>A) was closely related with cancer susceptibility, especially in Asian populations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25778331

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  12 in total

1.  The Role of ESR1 Gene Polymorphic Markers in the Development of Breast Cancer and Resistance to Tamoxifen Therapy.

Authors:  S S Lukina; A M Burdennyy; T M Zavarykina; D A Riabchikov; T P Kazubskaya; M P Kruglova; V I Loginov
Journal:  Bull Exp Biol Med       Date:  2021-01-16       Impact factor: 0.804

Review 2.  Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Authors:  S Salvi; V Conteduca; G Gurioli; D Calistri; V Casadio; U De Giorgi
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

3.  Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer Patients.

Authors:  Nasr M A Allahloubi; Abdel-Rahman N Zekri; Mohamed Ragab; Marwa Mohanad; Ola S Ahmed; Salem Eid; Mohamed Ghareeb; Iman Gouda; Abeer A Bahnassy
Journal:  Biochem Genet       Date:  2022-02-19       Impact factor: 1.890

Review 4.  Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.

Authors:  Tracey G Simon; Andrew T Chan
Journal:  Clin Liver Dis       Date:  2020-08-25       Impact factor: 6.126

5.  Association Between ESR1 PvuII, XbaI, and P325P Polymorphisms and Breast Cancer Susceptibility: A Meta-Analysis.

Authors:  Yiming Zhang; Ming Zhang; Xiaosong Yuan; Zhichen Zhang; Ping Zhang; Haojie Chao; Lixia Jiang; Jian Jiang
Journal:  Med Sci Monit       Date:  2015-10-04

6.  Succinct workflows for circulating tumor cells after enrichment: From systematic counting to mutational profiling.

Authors:  Victor Chun-Lam Wong; Josephine Mun-Yee Ko; Chi-Tat Lam; Maria Li Lung
Journal:  PLoS One       Date:  2017-05-08       Impact factor: 3.240

7.  Association of three single nucleotide polymorphisms of ESR1with breast cancer susceptibility: a meta-analysis.

Authors:  Xu Hu; Linfei Jiang; Chenhui Tang; Yuehong Ju; Li Jiu; Yongyue Wei; Li Guo; Yang Zhao
Journal:  J Biomed Res       Date:  2017-01-19

8.  Bioinformatics Analysis Identifies the Estrogen Receptor 1 (ESR1) Gene and hsa-miR-26a-5p as Potential Prognostic Biomarkers in Patients with Intrahepatic Cholangiocarcinoma.

Authors:  Xianzheng Qin; Yuning Song
Journal:  Med Sci Monit       Date:  2020-05-21

Review 9.  Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.

Authors:  Naoto Fujiwara; Scott L Friedman; Nicolas Goossens; Yujin Hoshida
Journal:  J Hepatol       Date:  2017-10-06       Impact factor: 30.083

Review 10.  Generic chemoprevention of hepatocellular carcinoma.

Authors:  Sai Krishna Athuluri-Divakar; Yujin Hoshida
Journal:  Ann N Y Acad Sci       Date:  2018-09-17       Impact factor: 6.499

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.